- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
lucemyra
Synonyms :
lofexidine
Class :
psychiatry agents, other
dosage forms & strengths
tablet
0.18mg
Indicated for opioid withdrawal
initial dose: 0.18 mg of three tablets (i.e.,0.54 mg) orally four times a day, while in the peak time of withdrawal symptoms (like the 5-7 days following opioid use
it should not exceed 2.88 mg of total dose in a day (i.e.,16 tablets)
it should not exceed 0.72 mg of a single dose in a day (i.e.,4 tablets)
therapy can be continued for nearly 14 days with dosing guided by the symptoms
for people who show a higher sensitivity, the dose can be decreased, held, or also discontinued
when opioid withdrawal symptoms get subside, the decreased dose may be suitable
discontinue by slowly decreasing the dose for over a 2-4 day period to alleviate the lofexidine withdrawal symptoms (like decreasing by one tablet/dose every one-two day)
safety and efficacy not established
refer to adult dosing
may have an increased AV-blocking effect when combined with beta-blockers
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may increase the AV-blocking effect of beta blockers
may increase the AV-blocking effect of beta blockers
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may decrease the diagnostic effect when combined with Alpha-/Beta-Agonists
may decrease the antihypertensive effect when combined with alpha2-agonists
may increase the vasoconstricting effect of Ergot Derivatives
It may increase the CNS depressant effect when combined with CNS Depressants
may enhance the effects of the other by pharmacodynamic synergism
may increase the hypertensive effect
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the qtc interval when combined with lofexidine
it may enhance the qtc interval when combined with lofexidine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the qtc interval when combined with lofexidine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the qtc interval when combined with lofexidine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the qtc interval when combined with lofexidine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the qtc interval when combined with lofexidine
it may enhance the qtc interval when combined with lofexidine
it may enhance the qtc interval when combined with lofexidine
it may enhance the qtc interval when combined with lofexidine
it may enhance the qtc interval when combined with lofexidine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the qtc interval when combined with lofexidine
it may enhance the qtc interval when combined with lofexidine
it may enhance the qtc interval when combined with lofexidine
it may enhance the qtc interval when combined with lofexidine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
lofexidine may enhance the CNS depressant effect of CNS depressants
lofexidine may enhance the CNS depressant effect of CNS depressants
lofexidine may enhance the CNS depressant effect of CNS depressants
lofexidine may enhance the CNS depressant effect of CNS depressants
lofexidine may enhance the CNS depressant effect of CNS depressants
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
lofexidine: they may increase the CNS depressant effect of CNS Depressants